BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxity

International Journal of Cardiology

Volumn 124, Issue 2, 2008, Pages 193-197

  Vogelsang, Thomas W ^a,b   Jensen, Ruben J ^a   Hesse, Birger ^a   Kjær, Andreas ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Anthracycline; BNP; Heart failure; LVEF; Radionuclide ventriculography

Indexed keywords

ANTHRACYCLINE; BRAIN NATRIURETIC PEPTIDE; TECHNETIUM 99M;

ARTICLE; CARDIAC PATIENT; CARDIOTOXICITY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG BLOOD LEVEL; HEALTH CARE COST; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NEOPLASM; PATIENT MONITORING; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY;

ADULT; AGED; ANTHRACYCLINES; COHORT STUDIES; CONFIDENCE INTERVALS; EVALUATION STUDIES AS TOPIC; FEMALE; GATED BLOOD-POOL IMAGING; HEART; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROBABILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 38649099703     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.02.003     Document Type: Article

References (11)

1. Von Hoff D.D., Rozencweig M., Layard M., Slavik M., and Muggia F.M. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 62 2 (Feb 1977) 200-208
2. Schwartz R.G., McKenzie W.B., Alexander J., et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 82 6 (Jun 1987) 1109-1118
3. Alexander J., Dainiak N., Berger H.J., et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300 6 (Feb 8 1979) 278-283
4. Kjaer A., and Hesse B. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clin Physiol 21 6 (Nov 2001) 661-672
5. Groenning B.A., Nilsson J.C., Sondergaard L., Kjaer A., Larsson H.B., and Hildebrandt P.R. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail 3 6 (Dec 2001) 699-708
6. Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clin 19 4 (Nov 2001) 557-571
7. Daugaard G., Lassen U., Bie P., et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7 1 (Jan 2005) 87-93
8. Okumura H., Iuchi K., Yoshida T., et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 104 4 (2000) 158-163
9. Nousiainen T., Vanninen E., Jantunen E., et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 251 3 (Mar 2002) 228-234
10. Nousiainen T., Jantunen E., Vanninen E., Remes J., Vuolteenaho O., and Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 62 2 (Feb 1999) 135-141
11. McDonagh T.A., Cunningham A.D., Morrison C.E., et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86 1 (Jul 2001) 21-26